Korea United Pharm Secures New Growth Engine? Korea United Pharm has obtained approval for Siloduo SR, a combination drug for the treatment of chronic arterial occlusive disease. What does this news mean for investors? This article analyzes the potential impact of Siloduo SR’s launch on Korea United Pharm’s stock price and highlights key factors to … Read more
A Game Changer in Hypertension Treatment? Analyzing Chong Kun Dang’s ‘Telminuvo Tab.’ Chong Kun Dang has sent ripples through the pharmaceutical market with its application for domestic approval of its new hypertension drug, Telminuvo Tab. Having shown positive results in Phase 3 clinical trials, could Telminuvo be the new growth engine for Chong Kun Dang? … Read more
Daewoong’s Nabota Faces Setback in China: Analysis and Outlook for Investors Daewoong Pharmaceutical’s voluntary withdrawal of its application for Nabota’s approval in China has sent ripples through the market. While this decision may negatively impact the stock price in the short term, what does it mean for the long-term outlook? This article provides investment strategies … Read more